Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer

Radiation Oncology
H YamashitaKeiichi Nakagawa

Abstract

Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional treatment for patients with stage II-III esophageal cancer. However, there are some demerits in this regimen because CDDP administration requires a large transfusion volume and 5-FU must be continuously infused over 24 h. Therefore, hospitalization is unavoidable. We collected retrospectively the data of definitive CRT with nedaplatin and S-1 as carried out in our institution. Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical surgery were included. Nedaplatin 80 mg/m(2) was given on days 1 and 29, and S-1 80 mg/m(2) on days 1-14 and 29-42. No prophylactic treatment with granulocyte colony stimulating factor was administered. Patients received two courses of concurrent radiotherapy of more than 50 Gy with or without two additional courses as adjuvant therapy every 4 weeks. Between August 2011 and June 2015, 89 patients (age range, 44-86 years; K-PS 90-100, 81 %; squamous cell carcinoma histology, 97 %; definitive/salvage CRT, 75/25 %) were collected. Twenty-one (24 %) patients completed four cycles, and 94 % received two or more cycles. Grade 4 leukopenia, thrombocytopenia, and anemia occ...Continue Reading

References

Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N UchidaT Yoshioka
Sep 16, 1999·International Journal of Radiation Oncology, Biology, Physics·M MurakamiH Takeda
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A OhtsuA Nakamura
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D MinskyDavid P Kelsen
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Satoshi IshikuraShigeaki Yoshida
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bunzo NakataKosei Hirakawa
Feb 25, 2005·International Journal of Clinical Oncology·Yasuhiro SatoYoshiro Niitsu
Sep 1, 2005·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·H YamashitaK Ohtomo
Aug 4, 2010·International Journal of Radiation Oncology, Biology, Physics·Hideomi YamashitaKeiichi Nakagawa
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Apr 5, 2013·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·R KobayashiK Nakagawa
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M StahlUNKNOWN ESMO Guidelines Working Group
Dec 4, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Hideomi YamashitaKeiichi Nakagawa

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
dissection

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.